Thus, a better understanding of PD-1, particularly in the tumor microenvironment, may provide insight into maximizing immunotherapy effectiveness, avoiding therapy-related toxicity, and ultimately guide the decision of which therapy to provide for individual patients [1,2]. Here, PDCD1 is linked to neoplasm.